This review updates major new findings and concepts introduced during the past year on the role of angiotensin II (Ang II) subtype 2 receptors (AT 2 Rs) in the control of blood pressure and renal function.
INTRODUCTION
The renin-angiotensin system (RAS) is a complex hormonal cascade governing cardiovascular and renal function [1, 2] . The RAS is composed of a major effector peptide, angiotensin II (Ang II), formed from renin-induced catalytic cleavage of angiotensinogen (renin substrate) to produce the decapeptide Ang I and subsequent cleavage by angiotensin converting enzyme (ACE) to synthesize the octapeptide Ang II. Ang II acts mainly via AT 1 receptors (AT 1 Rs) to initiate and maintain actions that can be detrimental to health, such as vasoconstriction, antinatriuresis, aldosterone secretion, sympathetic nervous system activation, cellular dedifferentiation and growth, inflammation, and target organ damage. The RAS is also composed of several other peptide metabolites and receptors, many of which oppose these actions. Most important and best studied are the ACE-2-Ang (1-7)-Mas receptor pathway and the Ang II/Ang III-AT 2 receptor (AT 2 R) pathway, both of which work to offset the actions of Ang II via AT 1 Rs. This review will focus on major new findings and concepts introduced during the past year on the role of AT 2 Rs in the control of blood pressure (BP) and renal function.
AT 2 R AGONIST-INDUCED NATRIURESIS AND BLOOD PRESSURE REDUCTION
AT 2 Rs are expressed throughout the adult kidney at vascular and tubule sites, albeit in smaller quantities than AT 1 Rs [3, 4] . In particular, AT 2 Rs are highly expressed in the renal proximal tubule (RPT) [4] . AT 2 R-induced natriuresis was first suggested 17 years ago when AT 2 R-null mice were shown to have pressor and antinatriuretic hypersensitivity to exogenous Ang II, indicating that pressure-natriuresis is reduced in the absence of AT 2 Rs [5] . The antinatriuresis in these animals was attributed to the marked reduction in renal bradykinin, nitric oxide, and guanosine cyclic 3 0 ,5 0 -monophosphate (cGMP) in AT 2 R-null compared with wild-type animals at baseline and in response to Ang II [5] .
Subsequently, studies found that the formal pressure-natriuresis relationship is indeed shifted to the right (less sensitive) in AT 2 R-null mice with and without L-N G -nitroarginine methyl ester (L-NAME)-induced hypertension [6, 7] .
Unequivocal evidence now exists that renal AT 2 Rs mediate natriuresis [8] [9] [10] [11] [12] [13] [14] [15] [16] . AT 2 Rs thereby oppose the actions of Ang II via AT 1 Rs, which increase renal tubule sodium (Na þ ) reabsorption and induce antinatriuresis [17] [18] [19] . Studies have demonstrated that the predominant, and possibly exclusive, endogenous AT 2 R agonist for the natriuretic response is not Ang II, but the Ang II metabolite [des-aspartyl 1 ]-Ang II (Ang III) ( Fig. 1) [9, 10, 16] . In normal animals, the demonstration of Ang III-mediated natriuresis via AT 2 Rs requires the presence of concurrent low-level systemic AT 1 R blockade or inhibition of aminopeptidase N, which catabolizes Ang III to inactive metabolites [8] [9] [10] 16] . In obese Zucker rats or streptozotocin-induced diabetic rats, however, concomitant AT 1 R blockade is not required because AT 2 Rs exhibit increased RPT AT 2 R expression in this model [11] [12] [13] [14] [15] . Interestingly, selective intrarenal AT 1 R blockade induces natriuresis by an AT 2 R-dependent mechanism that is blocked with AT 2 R antagonist PD-123319 (PD) [8] .
Although not formally examined, the mechanism of this acute response is likely related to increased endogenous intrarenal Ang III levels with consequent activation of unblocked AT 2 Rs [8] [9] [10] 16] .
Recent studies of AT 2 R-induced natriuresis have employed the highly selective nonpeptide AT 2 R agonist Compound 21 (C-21) [20, 21] . C-21 administered acutely to normal rats (systemically or intrarenally) induced natriuresis by an action at the RPT [22] . The C-21-induced natriuresis was mediated by AT 2 R activation, which was dependent upon a bradykininnitric oxide-cGMP signaling pathway, as previously described [23, 24] . Acute C-21 administration recruited AT 2 Rs from intracellular sites to the apical plasma membranes of RPT cells, a possible mechanism for reinforcing and sustaining the AT 2 R natriuretic response [22] . C-21 also internalized and inactivated major RPT Na þ transporters Na þ -hydrogen exchanger-3 (NHE-3) and Na þ /K þ ATPase (NKA), indicating that reduced RPT Na þ transport is the mechanism for the natriuresis [22] . Because no effective diuretic/natriuretic agents are available that act at the RPT, these observations suggested that AT 2 R activation might be additive to diuretics acting in the distal portions of the nephron (distal and connecting tubules and/or cortical collecting duct).
Recent studies have confirmed the natriuretic response of acute AT 2 R activation with intrarenal administration of highly selective AT 2 
KEY POINTS
Angiotensin AT 2 receptor (AT 2 R) activation induces natriuresis, maintains negative Na þ balance and lowers blood pressure chronically in angiotensindependent hypertension because of reduced Na þ reabsorption at the renal proximal tubule.
AT 2 R activation prevents salt-sensitive hypertension in the obese Zucker rat model of obesity and the metabolic syndrome.
Nitric oxide is both a product and a stimulator of AT 2 Rs, potentially reinforcing the AT 2 R biological response.
b-Pro-angiotensin III, a novel synthetic AT 2 R peptide agonist, reduces blood pressure in spontaneous hypertension.
AT 2 R activation improves renal structural and functional damage in high salt diet-fed obese Zucker rats. Building on the findings that acute AT 2 R activation induces natriuresis, Kemp et al. [28 && ] demonstrated in the Ang II infusion model of experimental hypertension that chronic AT 2 R activation with C-21 prevented the initial (24 h) Ang IIinduced reduction in Na þ excretion, induced sustained negative Na þ balance and lowered BP to nearcontrol levels during a 7-day infusion period. As with acute C-21 administration, concurrent AT 1 R blockade was not required to unmask the natriuretic and hypotensive actions of chronic C-21. Again, similar to the acute studies, chronic administration of C-21 was equally effective administered intrarenally or systemically, translocated AT 2 Rs to the apical plasma membranes and internalized/inactivated NHE-3 and NKA in RPT cells. C-21-induced natriuresis derived from RPT inhibition of Na þ reabsorption because it was additive to that of chlorothiazide and amiloride [28 && ]. In addition to preventing Na þ retention and hypertension, the results demonstrated that C-21 was equally effective in lowering BP once the Ang II-dependent hypertension had been established. This study strongly suggests that AT 2 R agonists can be effective natriuretic and diuretic agents that improve the pressurenatriuresis relationship and may be effective antihypertensive agents in settings in which the RAS is activated.
Whether AT 2 R agonists are antihypertensive by directly reducing peripheral vascular resistance, independently at least in part of their effects on renal Na þ excretion, has been controversial [29, 30] . Clear results have been hindered by lack of highly selective AT 2 R agonists for study. In order to circumvent this problem, Jones et al.
[31] applied a novel b-amino acid substitution to Ang II that resulted in more than 1000-fold selectivity of AT 2 R over AT 1 R binding. This compound, b-Ile 5 -Ang II, exhibited AT 2 R-dependent vasodepressor actions in vitro and was antihypertensive in spontaneously hypertensive rats (SHRs) in vivo in the presence of background low-level AT 1 R blockade [31] . Interestingly, previous studies showed that the heptapeptide Ang II metabolite, Ang III, elicited a biphasic BP response with an initial pressor response followed by a depressor response that was blocked by AT 2 R antagonist PD [32] . Building on these findings, Del Borgo et al. [33 && ] recently synthesized a new AT 2 R ligand, b-Pro-Ang III, with more than 20 000-fold AT 2 R to AT 1 R selectivity. This AT 2 R agonist evoked vasorelaxation in vitro and lowered BP acutely by approximately 35 mmHg during lowlevel AT 1 R blockade in conscious SHR. These vascular actions of b-Pro-Ang III were abolished by AT 2 R blockade with PD and also by bradykinin B 2 R antagonist icatibant or nitric oxide synthase (NOS) inhibitor L-NAME, indicating that they were caused by AT 2 R activation via the well-recognized bradykinin-nitric oxide AT 2 R signaling pathway in the vasculature [33 && ]. Of primary importance, the vasodepressor actions of Ang III and b-Pro-Ang III were much more impressive than those of Ang II under the same experimental conditions (in the presence of low-level AT 1 R blockade) [33 && ]. Similar to reports on natriuresis, these results demonstrate the differential effects of Ang III over Ang II on AT 2 R activation in the vasculature [8] [9] [10] 15, 33 && ].
POSITIVE NO FEEDBACK SIGNALING LOOP MAY REGULATE AT 2 R EXPRESSION
Among the cell signaling mechanisms that have been implicated in AT 2 R-induced biological responses in multiple organs and tissues, the bradykinin-nitric oxide-cGMP pathway is of paramount importance [34, 35] . AT 2 Rs can either activate NOS directly or indirectly via increased bradykinin production and subsequent activation of its B 2 Rs [36] . Indeed, mice lacking the B 2 R have normal BP and renal function, so direct NOS activation may serve as the default-signaling pathway [37] . Surprisingly, as reported recently, nitric oxide has been shown to upregulate the expression of AT 2 Rs in endothelial cells primarily by increasing AT 2 R gene expression (transcription) [38 & ]. Pharmacological inhibition of NOS with L-NAME reversed the upregulation of aortic AT 2 R expression in eNOS transgenic animals [38 & ]. As reported earlier, AT 2 R upregulation was associated with reduced activity of ACE [39] . Mice with increased AT 2 R expression had reduced ACE activity whereas AT 2 R-null mice manifested increased ACE activity [38 & ]. Thus, AT 2 Rs appear to be ACE inhibitors. When nitric oxide increased the AT 2 R message, the signaling pathway involved was increased soluble guanylyl cyclase activity increasing cGMP production, activation of protein kinase G (PKG) and p38 MAP kinase [38 & ]. Because AT 2 R activation increases synthesis and release of nitric oxide and cGMP, this finding raises the interesting possibility that a selective AT 2 R agonist, via a feed-forward mechanism involving nitric oxide generation, may in turn increase AT 2 R transcription, thus reinforcing vascular responses to the agonist chronically. This putative positive feedback mechanism might engender a favorable AT 2 R:AT 1 R ratio that could contribute to a sustained reduction of BP in response to chronic agonist administration. This exciting concept deserves further validation with experiments testing BP responses to chronic AT 2 R agonist administration. Whether this feed-forward concept also applies to cells and tissues other than endothelium awaits further study.
BENEFICIAL EFFECTS OF AT 2 R ACTIVATION IN OBESITY/METABOLIC SYNDROME
The obese Zucker rat is an established model of obesity with insulin resistance and mild hyperglycemia that approximates the metabolic syndrome in humans. This model has elevated BP and renal dysfunction [40] . Previous studies have shown that AT 2 R activation in the obese Zucker rat induces natriuresis by inactivating RPT NKA and exerts a protective role in lowering BP [11, [13] [14] [15] 41] . As indicated above, in the obese Zucker rat, activation of AT 2 Rs alone appears sufficient to lower BP without the addition of concurrent AT 1 R blockade [42] . This may be due to upregulation of AT 2 R expression by hyperglycemia. Furthermore, chronic AT 2 R blockade with PD increased BP in obese rats, suggesting a tonic protective role for AT 2 Rs on BP in this experimental model [41] .
Evidence for a role of AT 2 Rs in BP control in the obese Zucker model has now been reported [43 && ]. Chronic administration of C-21 over a 2-week period prevented a high-salt diet (HSD)-induced increase in BP in these animals [43 && ]. Ang II levels in the renal cortex were approximately four-fold higher in the HSD-fed rats than in their normal salt diet (NSD) controls. C-21 partially blocked the HSDinduced increase in renal Ang II levels and reduced renal AT 1 R protein expression by western blot analysis [43 && ]. Antibodies employed for AT 1 R detection, however, have been criticized as being nonspecific [44] . Interestingly, C-21 significantly increased 24 h urine Na þ excretion in both control and HSD-fed animals chronically (on days 11-14 of the study) [43 && ]. This observation is similar to earlier findings of an enhanced natriuresis in response to C-21 at 2 weeks in this model [42] and is reminiscent of the chronic negative Na þ balance induced by C-21 in the Ang II infusion model of experimental hypertension [28 && ], with obese Zucker rats and Ang II-infused rats having increased Ang II levels in common. Thus, pathophysiologic states characterized as having an activated RAS may respond best to the chronic natriuretic and BP lowering power of AT 2 R activation. Because AT 2 Rs are translocated to the apical plasma membranes of RPT cells [22, 28 && ] and do not internalize in renal epithelial cells [45] , these receptors likely remain active in promoting natriuresis without desensitization and, thereby, reducing BP over a prolonged period of time [46] .
In addition to a progressive Na þ -dependent increase in BP, obese Zucker rats also manifest salt-sensitive renal morphological changes of focal glomerulosclerosis [47] . AT 2 Rs have anti-inflammatory, antiproliferative, and antifibrotic effects, and may protect against oxidative stress [48] [49] [50] . A recent report sheds light on the pathophysiology of the renal dysfunction in obese Zucker rats fed HSD and demonstrates the attenuation of the renal target organ damage with AT 2 R activation via C-21 [51 && ]. HSD rats exhibited an increase in cortical nicotinamide adenine dinucleotide phosphate osidase activity, urinary hydrogen peroxide, and 8-isoprostanes, as well as severe glomerulosclerosis, interstitial fibrosis, reduction in glomerular filtration rate, urinary protein leak, and activity of Nacetyl-b-D-glucosaminidase, a lysosomal marker of tubular damage [51 && ]. C-21 significantly attenuated these changes. Although, further work needs to be done, particularly as to whether these C-21 effects are independent of reductions in BP, the results clearly show that AT 2 R activation protects against HSD-induced renal target organ damage in obesity.
CONCLUSION
AT 2 Rs constitute an important component of the 'protective arm' of the RAS, counter-balancing the untoward actions of the main RAS effector peptide, Ang II, via AT 1 Rs. The functions of AT 2 Rs have been more difficult to elicit than those of AT 1 Rs, at least in part because of the relatively low-expression level of AT 2 Rs compared with AT 1 Rs in adult cardiovascular and renal cells. With the recent development of highly selective AT 2 R agonists, however, the physiological and pathophysiological roles of these receptors are beginning to be clarified. Several concepts governing the role of AT 2 Rs in biological actions have emerged (Fig. 2) . First, AT 2 R activation seems to exert a beneficial role, such as natriuresis and/or hypotension, when the RAS is activated, as in Ang II-dependent hypertension or obesity with the metabolic syndrome. Second, AT 2 R beneficial effects are also observed when AT 1 Rs are blocked, so that AT 2 R responses are not swamped by AT 1 Rs and concurrently by facilitating stimulation of the unblocked AT 2 Rs. Third, the endogenous AT 2 R agonist (predominant or exclusive) appears to be the Ang II metabolite, Ang III. Fourth, because AT 2 Rs are recruited to plasma membranes and do not internalize, at least in renal epithelial cells, AT 2 R activation can sustain long-term beneficial effects, such as natriuresis, without desensitization. Fifth, AT 2 R activation has the capacity to improve or abolish target organ damage in certain cardiovascular and renal disease states. Many of these principles have been derived from work during the past year, which when coupled with past studies, have improved our understanding of the role of AT 2 Rs in pathophysiology and highlighted the promise of AT 2 R agonist therapy in the near future. 
